Abstract
Aurora B is a serine-threonine kinase belonging to the highly conserved Aurora family of mitotic kinases. Aurora B is a chromosomal passenger protein involved in chromosome segregation, spindle-checkpoint, and cytokinesis. Alteration of each of these steps could induce aneuploidy, one of main features, and driving force of cancer progression. The overexpression of Aurora B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. In this review we will focus on the role of Aurora B in cancer development, its role as a prognostic marker, and the clinical outcome of recently developed Aurora(s) inhibitors.
Keywords: Aurora kinase, Aurora B, serine-threonine kinase, mitosis, cytokinesis, cancer, inhibitors, Prognostic Marker, Therapeutic Target, aneuploidy, centrosome, chromosome, Testis Zinc Finger Protein (Tzfp), anaphase-promoting complex, phosphorylation, Cromosomal Passenger Complex, kinetochores, prometaphase, Survivin, INner CENtromere Pro-tein (INCENP), Histone Kinase, Tetrahymena thermophila, S. pombe, Saccharomyces cerevisiae, Drosophila, C. elegans, Xenopus, Spindle Checkpoint Kinase, microtubule-depolymerizing kinesin MCAK, Mi-totic Centromere-Associated Kinesin, Benzimidazoles, Cytokinesis Kinase, carcinoma, mesothelioma, glioblastoma, oral cancer, malignant en-dometrium, hepatocellular carcinoma, testicular germ, thyroid, colon, prostate, neoplastic lesions, Aurora Inhibitors, HESPERADIN, indolinone, chronic mye-loid leukemia (CML), acute lymphocytic leukemia
Current Medicinal Chemistry
Title: Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Volume: 18 Issue: 4
Author(s): G. Portella, C. Passaro and P. Chieffi
Affiliation:
Keywords: Aurora kinase, Aurora B, serine-threonine kinase, mitosis, cytokinesis, cancer, inhibitors, Prognostic Marker, Therapeutic Target, aneuploidy, centrosome, chromosome, Testis Zinc Finger Protein (Tzfp), anaphase-promoting complex, phosphorylation, Cromosomal Passenger Complex, kinetochores, prometaphase, Survivin, INner CENtromere Pro-tein (INCENP), Histone Kinase, Tetrahymena thermophila, S. pombe, Saccharomyces cerevisiae, Drosophila, C. elegans, Xenopus, Spindle Checkpoint Kinase, microtubule-depolymerizing kinesin MCAK, Mi-totic Centromere-Associated Kinesin, Benzimidazoles, Cytokinesis Kinase, carcinoma, mesothelioma, glioblastoma, oral cancer, malignant en-dometrium, hepatocellular carcinoma, testicular germ, thyroid, colon, prostate, neoplastic lesions, Aurora Inhibitors, HESPERADIN, indolinone, chronic mye-loid leukemia (CML), acute lymphocytic leukemia
Abstract: Aurora B is a serine-threonine kinase belonging to the highly conserved Aurora family of mitotic kinases. Aurora B is a chromosomal passenger protein involved in chromosome segregation, spindle-checkpoint, and cytokinesis. Alteration of each of these steps could induce aneuploidy, one of main features, and driving force of cancer progression. The overexpression of Aurora B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. In this review we will focus on the role of Aurora B in cancer development, its role as a prognostic marker, and the clinical outcome of recently developed Aurora(s) inhibitors.
Export Options
About this article
Cite this article as:
Portella G., Passaro C. and Chieffi P., Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480203
DOI https://dx.doi.org/10.2174/092986711794480203 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Current Cancer Drug Targets Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target
Current Pharmaceutical Design An Antileukemic Glutaminase Free L-Asparaginase from Bacillus brevis
Current Biotechnology p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Brain Tumor-Related Epilepsy
Current Neuropharmacology Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Reviews on Recent Clinical Trials Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs
Current Pharmaceutical Design T Cell Polarization and the Formation of Immunological Synapses: From Antigen Recognition to Virus Spread
Current Immunology Reviews (Discontinued) Prophylaxis of Cancer
Current Cancer Therapy Reviews Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Current Genomics Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets